Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth" report to their offering.

There has been vast scientific innovation within the CVD therapeutics market over recent decades, particularly within the anti-dyslipidemia market with the advent of statins such as Lipitor, the best-selling drug of all time, which produce marked reductions in cholesterol levels.

More recently, the commonly used direct factor Xa inhibitors which produce anti-coagulant effects, have been made available for oral administration and the advent of PCSK9 inhibitors provide a viable alternative dyslipidemia treatment for when statins are unsuitable or inefficient. There are currently 1368 pipeline drugs within the cardiovascular disease market, the largest therapy area being thrombosis, with 406 pipeline products indicated for treatment or prevention of thrombotic events.

Among those pipeline drugs expected for imminent release to market there is a mixture of first-in-class products, typically anti-dyslipidemia drugs aiming to provide alternatives to statin therapy, and drugs belonging to currently popular classes such as the aforementioned PCSK9 inhibitors and direct factor Xa inhibitors.

Key Topics Covered:

1 Tables & Figures

2 Introduction

2.1 Therapy Area Introduction

2.2 Symptoms

2.3 Etiology, Pathophysiology, Comorbidities and Complications

2.4 Diagnosis

2.5 Prognosis

2.6 Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation

2.7 Treatment

3 Key Marketed Products

3.1 Overview

3.2 Crestor (rosuvastatin) - AstraZeneca

3.3 Zetia (ezetimibe) - Merck & Co

3.4 Lipitor (atorvastatin) - Pfizer

3.5 Praluent (alirocumab) - Sanofi

3.6 Xarelto (rivaroxaban) - Bayer

3.7 Eliquis (apixaban) - Bristol-Myers Squibb and Pfizer

3.8 Plavix (clopidogrel) - Sanofi

3.9 Brilinta (ticagrelor) - AstraZeneca

3.10 Entresto (valsartan plus sacubitril) - Novartis

3.11 Benicar (olmesartan medoxomil) - Daiichi Sankyo

3.12 Conclusion

4 Pipeline Landscape Assessment

4.1 Overview

4.2 Pipeline Development Landscape

4.3 Molecular Targets in the Pipeline

4.4 Clinical Trials

4.5 Conclusion

5 Multi-Scenario Market Forecast to 2022

5.1 Overall Market Size

5.2 Generic Penetration

5.3 Revenue Forecast by Molecular Target

6 Company Analysis and Positioning

6.1 Company Landscape

6.2 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations

7.1 Licensing Deals

7.2 Co-development Deals

8 Appendix

Companies Mentioned

- AstraZeneca

- Bayer

- Bristol-Myers Squibb and Pfizer

- Daiichi Sankyo

- Merck & Co

- Novartis

- Pfizer

- Sanofi

For more information about this report visit http://www.researchandmarkets.com/research/jfmnpm/global

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Drugs